NCT07670624 T6A Biomarker for Detection of Bacterial Infection in Newborn Infants
| NCT ID | NCT07670624 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Salzburger Landeskliniken |
| Condition | Sepsis |
| Study Type | OBSERVATIONAL |
| Enrollment | 210 participants |
| Start Date | 2026-09-03 |
| Primary Completion | 2029-01-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 210 participants in total. It began in 2026-09-03 with a primary completion date of 2029-01-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This bi-center study aims to assess the efficacy of a new biomarker, N6-threonylcarbamoyladenosine (t6A), for the early diagnosis of Early-Onset Sepsis (EOS) in newborns.
Eligibility Criteria
Inclusion Criteria: * Newborn infants who require blood testing for screening for bacterial infection OR treating physician suspects bacterial infection in newborn infant * Signed informed consent form Exclusion Criteria: 1. Refusal to participate in study or not providing written informed consent by caregivers/parents 2. Antibiotic treatment of any kind.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07670624 clinical trial?
This trial is open to participants of all sexes, studying Sepsis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07670624 currently recruiting?
Yes, NCT07670624 is actively recruiting participants. Contact the research team at L.stana-hackenberg@salk.at for enrollment information.
Where is the NCT07670624 trial being conducted?
This trial is being conducted at Salzburg, Austria, Wroclaw, Poland.
Who is sponsoring the NCT07670624 clinical trial?
NCT07670624 is sponsored by Salzburger Landeskliniken. The trial plans to enroll 210 participants.